Clinical Scorecard: Identification of a Resilient Group Against Acute Kidney Injury: Findings from Septic Shock Patients

At a Glance

Key Highlights

• Sepsis-associated AKI occurs in 40–50% of septic patients and increases mortality three to five-fold.
• [TIMP-2]•[IGFBP7] and KIM-1 biomarkers enable identification of kidney stress and subclinical injury before clinical AKI develops.
• A subset of patients with high kidney stress biomarkers but no clinical or biomarker evidence of AKI were identified as AKI-resistant.

Guideline-Based Recommendations

Diagnosis

• Use KDIGO criteria combining serum creatinine and urine output to classify AKI.
• Measure urinary [TIMP-2]•[IGFBP7] at 6 hours post-resuscitation to assess kidney stress.
• Use urinary KIM-1 levels to detect subclinical kidney injury not evident by KDIGO criteria.

Management

• Recognize patients with elevated [TIMP-2]•[IGFBP7] but no AKI as a distinct AKI-resistant group.
• Continue standard septic shock resuscitation protocols as per ProCESS trial guidelines.

Monitoring & Follow-up

• Monitor serum creatinine and urine output daily for up to 7 days post-enrollment.
• Repeat biomarker measurements as clinically indicated to assess kidney stress and injury progression.

Risks

• Patients with elevated kidney stress biomarkers and clinical AKI have increased morbidity and mortality.
• Failure to identify subclinical injury may delay intervention and worsen outcomes.

Patient & Prescribing Data

Patients with septic shock enrolled in the ProCESS trial excluding those with ESRD or baseline serum creatinine >4 mg/dL

Biomarker-guided identification of AKI resistance may inform prognosis but does not currently alter standard resuscitation treatment.

Clinical Best Practices

• Incorporate biomarker testing ([TIMP-2]•[IGFBP7] and KIM-1) alongside clinical criteria to stratify AKI risk in septic shock patients.
• Use a [TIMP-2]•[IGFBP7] cutoff >1.0 (ng/mL)2/1000 to indicate significant kidney stress.
• Use a KIM-1 cutoff ≤2 ng/mL to define absence of subclinical kidney injury.
• Classify patients as AKI-resistant if they have high kidney stress biomarkers without clinical or biomarker evidence of AKI.
• Focus on early identification of AKI risk to potentially improve patient-centered outcomes.

References

• KDIGO Clinical Practice Guideline for Acute Kidney Injury
• ProCESS Trial Primary Results
• NephroCheck Test for AKI Risk Assessment